Burnham Asset Management Corp Ny Lowers stake in Edwards Lifesciences Corp (EW)

Edwards Lifesciences Corp (EW) : Burnham Asset Management Corp Ny reduced its stake in Edwards Lifesciences Corp by 1.12% during the most recent quarter end. The investment management company now holds a total of 41,650 shares of Edwards Lifesciences Corp which is valued at $4.3 Million after selling 470 shares in Edwards Lifesciences Corp , the firm said in a disclosure report filed with the SEC on May 13, 2016.Edwards Lifesciences Corp makes up approximately 1.36% of Burnham Asset Management Corp Ny’s portfolio.

Other Hedge Funds, Including , Pacer Advisors reduced its stake in EW by selling 4 shares or 0.11% in the most recent quarter. The Hedge Fund company now holds 3,682 shares of EW which is valued at $379,209. Edwards Lifesciences Corp makes up approx 0.08% of Pacer Advisors’s portfolio.Picton Mahoney Asset Management boosted its stake in EW in the latest quarter, The investment management firm added 245,050 additional shares and now holds a total of 434,950 shares of Edwards Lifesciences Corp which is valued at $44.8 Million. Edwards Lifesciences Corp makes up approx 3.06% of Picton Mahoney Asset Management’s portfolio.Norges Bank reduced its stake in EW by selling 185,336 shares or 10.05% in the most recent quarter. The Hedge Fund company now holds 1,658,650 shares of EW which is valued at $170.8 Million. Edwards Lifesciences Corp makes up approx 0.09% of Norges Bank’s portfolio.De Burlo Group Inc boosted its stake in EW in the latest quarter, The investment management firm added 200 additional shares and now holds a total of 109,100 shares of Edwards Lifesciences Corp which is valued at $11.5 Million. Edwards Lifesciences Corp makes up approx 3.36% of De Burlo Group Inc’s portfolio.

Edwards Lifesciences Corp closed down -1.58 points or -1.56% at $99.91 with 15,25,779 shares getting traded on Wednesday. Post opening the session at $101.79, the shares hit an intraday low of $99.69 and an intraday high of $101.96 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

On the company’s financial health, Edwards Lifesciences Corp reported $0.71 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Apr 26, 2016. Analyst had a consensus of $0.66. The company had revenue of $697.30 million for the quarter, compared to analysts expectations of $666.93 million. The company’s revenue was up 18.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.12 EPS.

Many Wall Street Analysts have commented on Edwards Lifesciences Corp. Company shares were Reiterated by Canaccord Genuity on May 23, 2016 to “Buy”, Firm has raised the Price Target to $ 132 from a previous price target of $123 .Company shares were Reiterated by RBC Capital Mkts on Apr 27, 2016 to “Outperform”, Firm has raised the Price Target to $ 125 from a previous price target of $110 .Company shares were Reiterated by Canaccord Genuity on Apr 27, 2016 to “Buy”, Firm has raised the Price Target to $ 123 from a previous price target of $113 .

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting. Patients in the hospital setting including high-risk patients in the operating room or intensive care unit are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Company’s products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy Surgical Heart Valve Therapy and Critical Care.

Leave a Reply

Edwards Lifesciences Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Edwards Lifesciences Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.